- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
SILVER SPRING, Md. A popular beauty treatment has won approval as a medical treatment as well.
The Food and Drug Administration announced Friday the approval of Allergan’s Botox (onabotulinumtoxinA) for preventing headaches in adult patients with chronic migraine.
“Chronic migraine is one of the most disabling forms of headache,” FDA division of neurology products director Russell Katz said. “Patients with chronic migraine experience a headache more than 14 days of the month. This condition can greatly affect family, work and social life, so it’s important to have a variety of effective treatments available.”